HIND Company Profile and Key Details

HIND has shown weak momentum, losing -14.55% over the past week and -47.73% over the past quarter, though year-to-date performance is down -19.77%. Short-term trend indicators are bullishly aligned (SMA20 27.93%, SMA50 9.5%, SMA200 -57.44%). The stock’s 14-day RSI is 59.6 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.9% below its high and over 92.0% above its low. Average 10-day trading volume of 7.58 thousand shares is below the 3-month average of 12.06 thousand, indicating normal recent market interest.

Vyome Holdings, Inc. has 7.02 million shares outstanding. The public float is 3.65 million shares, elevated short interest at 0.61% of float. This equals 27.39 thousand shares. The short ratio is 2.02 days. Institutional investors hold 3.23% of the float. Insiders own 52.88%.

Vyome Holdings, Inc. (NASDAQ:HIND) closed at $2.10 USD, gaining $0.04 (1.94%) from the previous close of $2.06. The stock is currently mid-range between its 52-week high and low $1.75 and $9.56. With a market capitalization of about $14.74 million, Vyome Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.51). Key stats such as the average daily volume over the past year has been around 12.28 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Vyome Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Venkateswarlu Nelabhotla, the company employs approximately 18 people and listed since October 06, 2016. Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders.

Vyome Holdings, Inc. generated EPS of -$177.38 over the past year. Five-year average earnings growth is 80.05%. Wall Street analysts project EPS growth of 90.07% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $3.50. The high target offers 614.29% upside. The low target suggests 66.67% downside. The mean target is $9.25. This offers 340.48% upside. Vyome Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -47.37%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -53.45% in April 04, 2025.

Vyome Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.07. This means the shares are trading near this model’s fair value.

Vyome Holdings, Inc. trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 111.45 and a price-to-book ratio of 2.39 suggesting the stock is closer to book value. The P/FCF stands at 27.57, also above market averages.

Our AI price prediction model suggests that Vyome Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.29%, with price expected at $2.01 by September 24, 2026, within a range of $1.95 to $2.07 3-Month Outlook: Projected rise of 58.1%, reaching $3.32 by December 08, 2026, with a range of $3.11 to $3.48. 1-Year Outlook: Projected gain of 98.1%, with price at $4.16 by September 10, 2027, within a range of $2.65 to $4.50.

Vyome Holdings, Inc. (NASDAQ:HIND) shares are down -19.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vyome Holdings, Inc. trading at a premium to the broader market with a P/E of -0.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.25, suggesting 340.48% upside. Our AI forecast model points to short-term weakness (-4.29% over two weeks), a medium-term rise (58.1% over three months), and a longer-term gain (98.1% over one year), with expected trading ranges indicating moderate volatility.